
November 26, 2017 - By Migdalia James
Among 5 analysts covering Immune Design (NASDAQ:IMDZ), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Immune Design had 10 analyst reports since August 18, 2015 according to SRatingsIntel. The rating was maintained by Jefferies on Monday, June 26 with “Buy”. As per Tuesday, June 6, the company rating was maintained by Cowen & Co. The company was maintained on Wednesday, October 18 by Wells Fargo. Leerink Swann initiated Immune Design Corp (NASDAQ:IMDZ) rating on Tuesday, August 18. Leerink Swann has “Outperform” rating and $40 target. Jefferies initiated the stock with “Buy” rating in Wednesday, September 9 report. Jefferies maintained it with “Buy” rating and $18.0 target in Monday, September 4 report. The firm has “Buy” rating given on Wednesday, August 10 by Jefferies. Jefferies maintained it with “Buy” rating and $18.0 target in Thursday, October 5 report. See Immune Design Corp (NASDAQ:IMDZ) latest ratings:18/10/2017 Broker: Wells Fargo Rating: Market Perform Old Target: $29 New Target: $10 Maintain05/10/2017 Broker: Jefferies Rating: Buy New Target: $18.0 Maintain15/09/2017 Broker: RBC Capital Markets Rating: Outperform New Target: $20 Initiates Coverage On04/09/2017 Broker: Jefferies Rating: Buy New Target: $18.0 Maintain26/06/2017 Broker: Jefferies Rating: Buy New Target: $18.0000 Maintain06/06/2017 Broker: Cowen & Co Rating: Buy MaintainKcm Investment Advisors Llc decreased Glaxosmithkline Plc (GSK) stake by 73.66% reported in 2017Q2 SEC filing. Kcm Investment Advisors Llc sold 18,963 shares as Glaxosmithkline Plc (GSK)’s stock rose 5.47%. The Kcm Investment Advisors Llc holds 6,780 shares with $292,000 value, down from 25,743 last quarter. Glaxosmithkline Plc now has $85.10 billion valuation. The stock decreased 0.06% or $0.02 on November 24, reaching $35.04. About 1.74M shares traded. GlaxoSmithKline plc (ADR) (NYSE:GSK) has risen 4.26% since November 26, 2016 and is uptrending. It has underperformed by 12.44% the S&P500.Among 15 analysts covering GlaxoSmithKline (NYSE:GSK), 6 have Buy rating, 1 Sell and 8 Hold. Therefore 40% are positive. GlaxoSmithKline had 23 analyst reports since September 8, 2015 according to SRatingsIntel. The company was upgraded on Tuesday, September 8 by Bank of America. The firm earned “Neutral” rating on Monday, October 12 by JP Morgan. The rating was upgraded by Bryan Garnier & Cie on Wednesday, January 27 to “Buy”. BNP Paribas downgraded the stock to “Underperform” rating in Wednesday, September 14 report. The firm earned “Buy” rating on Thursday, October 20 by Investec. Argus Research maintained GlaxoSmithKline plc (ADR) (NYSE:GSK) on Monday, December 7 with “Buy” rating. The rating was downgraded by Citigroup to “Neutral” on Wednesday, July 5. The firm has “Buy” rating given on Wednesday, December 9 by Bank of America. The firm has “Neutral” rating given on Tuesday, September 15 by BNP Paribas. The rating was downgraded by Morgan Stanley on Friday, September 8 to “Underweight”.Kcm Investment Advisors Llc increased U S Bancorp (NYSE:USB) stake by 16,843 shares to 96,946 valued at $5.03 million in 2017Q2. It also upped Microsoft Corp (NASDAQ:MSFT) stake by 8,559 shares and now owns 345,719 shares. Bancofcalifornia 7.375. Ca2020 was raised too. Analysts await GlaxoSmithKline plc (ADR) (NYSE:GSK) to report earnings on February, 14. They expect $0.64 EPS, down 1.54% or $0.01 from last year’s $0.65 per share. GSK’s profit will be $1.55 billion for 13.69 P/E if the $0.64 EPS becomes a reality. After $0.85 actual EPS reported by GlaxoSmithKline plc (ADR) for the previous quarter, Wall Street now forecasts -24.71% negative EPS growth. Investors sentiment increased to 2.44 in 2017 Q2. Its up 1.44, from 1 in 2017Q1. It is positive, as 8 investors sold Immune Design Corp shares while 8 reduced holdings. 13 funds opened positions while 26 raised stakes. 10.96 million shares or 2.86% more from 10.66 million shares in 2017Q1 were reported. Rhumbline Advisers has 0% invested in Immune Design Corp (NASDAQ:IMDZ) for 19,694 shares. The New York-based Renaissance Tech Ltd Llc has invested 0% in Immune Design Corp (NASDAQ:IMDZ). Barclays Public Limited Liability Co owns 0% invested in Immune Design Corp (NASDAQ:IMDZ) for 12 shares. Art Advsr Limited Liability Corp has 14,430 shares for 0.01% of their portfolio. Dimensional Fund Advsrs Lp holds 18,896 shares. Tiaa Cref Invest Mngmt Limited Company holds 0% or 65,219 shares. American Intll Grp holds 10,577 shares or 0% of its portfolio. Proquest Assoc Iv Limited Liability accumulated 1.96 million shares. Savings Bank Of America De reported 12,523 shares or 0% of all its holdings. Vanguard Group Inc Incorporated owns 0% invested in Immune Design Corp (NASDAQ:IMDZ) for 524,999 shares. Connor Clark And Lunn Invest Management Ltd holds 26,630 shares or 0% of its portfolio. The New York-based Blackrock has invested 0% in Immune Design Corp (NASDAQ:IMDZ). Fmr Lc accumulated 0% or 411,341 shares. Moreover, Bnp Paribas Arbitrage Sa has 0% invested in Immune Design Corp (NASDAQ:IMDZ) for 1,575 shares. State Of Wisconsin Inv Board reported 12,000 shares.Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.


var data = "63557954";
document.write('<ins class="adsbygoogle" style="background-color:transparent; display:inline-block;width:300px;height:600px;" data-ad-client="ca-pub-16900'+data+'675" data-ad-slot="7169126944"></ins>')

(adsbygoogle = window.adsbygoogle || []).push({});